Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Okayama University Makes a Breakthrough in Retinal Degeneration


News provided by

Okayama University

10 Jul, 2018, 08:32 GMT

Share this article

Share toX

Share this article

Share toX

OKAYAMA, Japan, July 10, 2018 /PRNewswire/ --

Researchers at Okayama University report in the journal Artificial Organs the successful implantation of dye-based prosthetic films in monkey eyes. The study demonstrates the implantation's surgical feasibility, and marks an important step towards the development of a treatment for patients with macular degeneration or retinitis pigmentosa.

This image opens in the lightbox
Sequence of surgical procedures for implanting Okayama University-type retinal prosthesis in a monkey eye (PRNewsfoto/Okayama University)

     (Photo: https://mma.prnewswire.com/media/711873/Okayama_University_Infographic.jpg )

With age, the macula - a pigmented area near the center of the retina in the human eye - often becomes damaged, resulting in deteriorated vision. Nearly 12% of people aged 80 or older suffer from such age-related blurred or lost center-of-field vision, known medically as macular degeneration. At present, there is no treatment for recovering lost vision due to macular degeneration, but a team of researchers led by Dr.Toshihiko Matsuo from Okayama University are making significant progress towards implants that could replace damaged maculas in humans.

Dr.Matsuo and colleagues succeeded in surgically inserting a retinal implant, known as Okayama University-type retinal prosthesis (OUReP[TM]), in the subretinal space of monkey eyes suffering from macular degeneration. OUReP[TM], developed earlier at Okayama University, is a material based on photoelectric dye molecules, capable of converting light into electric potentials, and as such mimicking phototransduction as it takes place in mammalian eyes.

The researchers worked with cynomolgus monkeys, in which macular degeneration was induced in one eye through injections with cobalt chloride. Initial experiments done with 6 monkeys during one month were followed by tests on 8 monkeys in a 6-month period. In the latter study, 3 monkeys underwent surgery after 5 months for inspection of the OUReP[TM] implant. Monkeys were not only used because their retinas, like human retinas, have a macular structure, but also because monkey studies are a necessary intermediate step, required by Japan's Pharmaceuticals and Medical Devices Agency, towards the development of implants for human eyes.

All monkeys involved in the experiments were healthy during the observation period. Dr.Matsuo and colleagues demonstrated the surgical feasibility of implanting OUReP[TM]; the neuroretina (the part containing the retina's neural elements) remained attached to the dye films through the 1- and 6-month periods, and structural integrity of the implantation site was observed as well. Furthermore, the researchers checked that no monkeys developed retinal toxicity or inflammatory cells. The implants' functioning was tested by measurements of the amplitude of visually evoked potentials; normal signal amplitudes were observed one month after implantation and remained stable after.

The scientists point out that OUReP[TM] implants could also become applicable as a treatment for retinitis pigmentosa, a hereditary retinal disease causing blindness due to dead photoreceptor cells. Quoting Dr.Matsuo and colleagues: "The filing of a first-in-human clinical trial for OUReP[TM] in patients who have lost vision by retinitis pigmentosa is now negotiated at Pharmaceuticals and Medical Devices Agency (PMDA) in Japan."

About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences. Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

Website: http://www.okayama-u.ac.jp/index_e.html

Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm@adm.okayama-u.ac.jp

Website: http://www.okayama-u.ac.jp/index_e.html

Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

Reference 1

Toshihiko Matsuo, Tetsuya Uchida, Jun Sakurai, Koichiro Yamashita, Chie Matsuo, Tomoaki Araki, Yusuke Yamashita, Kunihisa Kamikawa. Visual Evoked Potential Recovery by Subretinal Implantation of Photoelectric Dye‐Coupled Thin Film Retinal Prosthesis in Monkey Eyes With Macular Degeneration. Artificial Organs, 42, 2018.

DOI : 10.1111/aor.13120

https://onlinelibrary.wiley.com/doi/full/10.1111/aor.13120

Reference 2

Toshihiko MATSUO, Tetsuya UCHIDA, Makoto NITTA, Koichiro YAMASHITA, Shigiko TAKEI, Daisuke IDO, Mamoru TANAKA, Masao OGUCHI, Toshinori FURUKAWA. Subretinal implantation of Okayama University-type retinal prosthesis (OUReP[TM]) in canine eyes by vitrectomy. Journal of Veterinary Medical Science, Volume 79 (2017), Issue 12, Pages 1939-1946.

DOI : https://doi.org/10.1292/jvms.17-0450

https://www.jstage.jst.go.jp/article/jvms/79/12/79_17-0450/_article

Reference 3

Toshihiko MATSUO, Tetsuya UCHIDA, Koichiro YAMASHITA, Shigiko TAKEI, Daisuke IDO, Mamoru TANAKA, Masao OGUCHI, Toshinori FURUKAWA. Visual evoked potential in rabbits' eyes with subretinal implantation by vitrectomy of Okayama University-type retinal prosthesis (OUReP[TM]). Journal of Veterinary Medical Science, Vol. 80 (2018), No. 2 pp. 247-259.

DOI : https://doi.org/10.1292/jvms.17-0422

https://www.jstage.jst.go.jp/article/jvms/advpub/0/advpub_17-0422/_article

Reference (Okayama Univ. e-Bulletin): Associate Professor Matsuo's team  

e-Bulletin Vol.8:Photoelectric dye-coupled thin film as a novel type of retinal prosthesis

OU-MRU Vol.8:Light-responsive dye stimulates sight in genetically blind patients

OU-MRU Vol.39:Successful test of retinal prosthesis implanted in rats

OU-MRU Vol.47:Candidate genes for eye misalignment identified

.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.